




Martín Avalos, Reyes Babiano, Pedro Cintas, Fernando R. Clemente,
Ruth Gordillo, Michael B. Hursthouse, José L. Jiménez,*
Mark E. Light and Juan C. Palacios

Tetrahedron: Asymmetry 12 (2001) 2261



$[\alpha]_{578} = -1442.4$ (*c* 0.7, CHCl₃)



Source of chirality: chiral precursor



(3a*R*,4*R*,6a*S*)-4-(1',2',3'-Tri-*O*-acetyl-*D*-erythro-tritol-1-yl)-2-(*N*-methyl)benzylamino-6a-phenyl-3-[*(1E)*-phenylazo]-3a*H*,4*H*,6a*H*-thieno[2,3-*c*]furan-6-one

Martín Avalos, Reyes Babiano, Pedro Cintas, Fernando R. Clemente,
Ruth Gordillo, Michael B. Hursthouse, José L. Jiménez,*
Mark E. Light and Juan C. Palacios

Tetrahedron: Asymmetry 12 (2001) 2261



$[\alpha]_{578} = -1058.9$ (*c* 0.9, CHCl₃)



Source of chirality: chiral precursor



(3a*R*,4*R*,6a*S*)-4-(1',2',3'-Tri-*O*-acetyl-*D*-erythro-tritol-1-yl)-3-[*(1E)*-(4-methoxyphenyl)azo]-2-(*N*-methyl)-benzylamino-6a-phenyl-3a*H*,4*H*,6a*H*-thieno[2,3-*c*]furan-6-one

Martín Avalos, Reyes Babiano, Pedro Cintas, Fernando R. Clemente,
Ruth Gordillo, Michael B. Hursthouse, José L. Jiménez,*
Mark E. Light and Juan C. Palacios

Tetrahedron: Asymmetry 12 (2001) 2261



$[\alpha]_{578} = -1365.4$ (*c* 1.1, CHCl₃)


Source of chirality: chiral precursor



(3a*R*,4*R*,6a*S*)-4-(1',2',3'-Tri-*O*-acetyl-*D*-erythro-tritol-1-yl)-3-[*(1E)*-(4-chlorophenyl)azo]-2-(*N*-methyl)-benzylamino-6a-phenyl-3a*H*,4*H*,6a*H*-thieno[2,3-*c*]furan-6-one


Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265



$[\alpha]_D = +165.6$ (*c* 0.4, CHCl₃)


Source of chirality: asymmetric synthesis



(2*R*,3*R*)-3-(Tetra-*O*-acetyl-*D*-arabino-tetritol-1'-yl)-2-[4-benzyl-2-(4-nitrophenyl)-1,3-dioxo-2,4-diazapentyl]-2-phenylthiirane

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




$[\alpha]_D = -170.6$ (*c* 0.8, CHCl₃)

Source of chirality: asymmetric synthesis

C₃₆H₃₇N₃O₁₂S
(2S,3S)-3-(Tetra-O-acetyl-D-arabino-tetritol-1'-yl)-2-[4-benzyl-2-(4-nitrophenyl)-1,3-dioxo-2,4-diazapentyl]-2-phenylthiirane

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*


Tetrahedron: Asymmetry 12 (2001) 2265



C₃₆H₃₈N₂O₁₀S
(2R,3S)-3-(Tetra-O-acetyl-D-arabino-tetritol-1'-yl)-2-(4-benzyl-1,3-dioxo-2-phenyl-2,4-diazapentyl)-2-phenylthiirane

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*


Tetrahedron: Asymmetry 12 (2001) 2265



C₃₆H₃₈N₂O₁₀S
(2R,3R)-3-(Tetra-O-acetyl-D-arabino-tetritol-1'-yl)-2-(4-benzyl-1,3-dioxo-2-phenyl-2,4-diazapentyl)-2-phenylthiirane

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*


Tetrahedron: Asymmetry 12 (2001) 2265



C₃₆H₃₈N₂O₁₀S
(2S,3S)-3-(Tetra-O-acetyl-D-arabino-tetritol-1'-yl)-2-(4-benzyl-1,3-dioxo-2-phenyl-2,4-diazapentyl)-2-phenylthiirane

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




$$[\alpha]_D = +110.1 \text{ (} c \text{ 1.2, CHCl}_3 \text{)}$$

Source of chirality: asymmetric synthesis

$(2R,3R)-3\text{-}(\text{Tetra-}O\text{-acetyl-D-}arabino\text{-}tetritol-1'\text{-yl})\text{-}2\text{-[4-benzyl-2-(4-methoxyphenyl)-1,3-dioxo-2,4-diazapentyl]-2-phenylthiurane}$

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




$$[\alpha]_D = -88.3 \text{ (} c \text{ 0.4, CHCl}_3 \text{)}$$

Source of chirality: asymmetric synthesis

$\text{C}_{37}\text{H}_{40}\text{N}_2\text{O}_{11}\text{S}$
 $(2S,3S)-3-(\text{Tetra}-O\text{-acetyl-D-}arabino\text{-tetritol-1'-yl})-2\text{-[4-benzyl-2-(4-methoxyphenyl)-1,3-dioxo-2,4-diazapentyl]-2-phenylthiirane}$

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




$[\alpha]_D = -18.5$ (*c* 0.1, CHCl₃)

Source of chirality: chiral precursor

(E)-*N*-(*N'*-Benzyl-*N'*-methylcarbamoyl)-*N*-(4-nitrophenyl)-2,3-dideoxy-2-phenyl-tetra-*O*-acetyl-*D-arabino*-hept-2-enamide

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




$$[\alpha]_D = -167.6 \text{ (} c \text{ 0.3, CHCl}_3 \text{)}$$

Source of chirality: chiral precursor

(Z) -*N*-(*N'*-Benzyl-*N'*-methylcarbamoyl)-*N*-(4-methoxyphenyl)-2,3-dideoxy-2-phenyl-tetra-*O*-acetyl-*D*-arabino-hept-2-enamide

Martín Avalos, Reyes Babiano, Pedro Cintas,
Fernando R. Clemente, Ruth Gordillo, Michael B. Hursthouse,
José L. Jiménez, Mark E. Light and Juan C. Palacios*

Tetrahedron: Asymmetry 12 (2001) 2265




C₃₇H₄₀N₂O₁₁
(*E*)-*N*-(*N'*-Benzyl-*N'*-methylcarbamoyl)-*N*-(4-methoxyphenyl)-2,3-dideoxy-2-phenyl-tetra-*O*-acetyl-*D*-arabino-hept-2-enamide

[α]_D = +11.2 (*c* 0.3, CHCl₃)

Source of chirality: chiral precursor

Ramaiah Kumareswaran and Alfred Hassner*

Tetrahedron: Asymmetry 12 (2001) 2269



C₁₉H₃₁NOS
(*S*)-(+)-*N*-Dodecylidene-*p*-toluenesulfinamide

E.e. >98%


[α]_D²⁵ 176.3 (*c* = 1.9, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*S*)

Ramaiah Kumareswaran and Alfred Hassner*

Tetrahedron: Asymmetry 12 (2001) 2269



C₂₀H₂₅NO₃S₂
(3*S*)-Phenylsulfonyl-(4*R*)-[*N*-(*p*-tolylsulfinyl)amino]hept-1-ene

E.e. >98%


[α]_D²⁵ +141.4 (*c* = 1.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)

Ramaiah Kumareswaran and Alfred Hassner*

Tetrahedron: Asymmetry 12 (2001) 2269




C₁₃H₁₉NO₂S
(4*R*)-Amino-(3*S*)-phenylsulfonylhept-1-ene

E.e. >98%

[α]_D²⁵ -73.1 (*c* = 1.3, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (3*S*,4*R*)

(4R)-*N*-(2-Propenyl)amino-(3*S*)-phenylsulfonylhept-1-ene

E.e. >98%

 $[\alpha]_{D}^{25} -48.2$ ($c = 0.85$, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)(4R)-*N*-(2-Propenyl)acetamido-(3*S*)-phenylsulfonylpentadec-1-ene

E.e. = 32%

 $[\alpha]_{D}^{25} -3.6$ ($c = 3.9$, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)N-Acetyl-(5*S*)-phenylsulfonyl-(6*R*)-*n*-undecyl-1,2,5,6-tetrahydropyridine

E.e. = 32%

 $[\alpha]_{D}^{25} +52.5$ ($c = 1.6$, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (5*S*,6*R*)(5*S*)-Phenylsulfonyl-(6*R*)-*n*-undecyl-1,2,5,6-tetrahydropyridine

E.e. = 32%

 $[\alpha]_{D}^{25} +38$ ($c = 1.05$, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (5*S*,6*R*)




$C_{18}H_{25}NO_3S$
(4*R*)-*N*-(2-Propenyl)-*N*-acetylamino-(3*S*)-phenylsulfonylhept-1-ene

E.e. >98%

 $[\alpha]_D^{25} -30$ ($c=2$, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (3*S*,4*R*)

$C_{16}H_{26}NO_3S$
N-Acetyl-(5*S*)-phenylsulfonyl-(6*R*)-*n*-propyl-1,2,5,6-tetrahydropyridine

E.e. >98%

 $[\alpha]_D^{25} +196$ ($c=1.2$, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (5*S*,6*R*)

$C_{16}H_{23}NO_3S$
N-Acetyl-(2*R*)-*n*-propyl-(3*S*)-phenylsulfonylpiperidine

E.e. >98%

 $[\alpha]_D^{25} = -16$ ($c=2.25$, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*R*,3*S*)


$C_{10}H_{19}NO$
N-Acetyl-(*R*)-coniine

E.e. >99%

 $[\alpha]_D^{25} = -48.6$ ($c=0.72$, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: *R*

(3S)-Phenylsulfonyl-(4R)-[N-(*p*-tolylsulfinyl)amino]pentadec-1-ene

E.e. = 32%

 $[\alpha]_{D}^{25} +108$ ($c = 1.5$, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (S_s,3S,4R)


(4R)-Amino-(3S)-phenylsulfonylpentadec-1-ene

E.e. = 32%

 $[\alpha]_{D}^{25} -15.3$ ($c = 1.5$, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4R)




(4R)-N-(2-Propenyl)amino-(3S)-phenylsulfonylpentadec-1-ene

E.e. = 32%

 $[\alpha]_{D}^{25} -15.8$ ($c = 1.9$, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4R)




N-Boc-(5S)-phenylsulfonyl-(6R)-n-undecyl-1,2,5,6-tetrahydropyridine

E.e. = 32%

 $[\alpha]_{D}^{25} +29.6$ ($c = 2.6$, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (5S,6R)

*N*-Boc-(2*R*)-*n*-undecyl-(3*S*)-phenylsulfonylpiperidine

E.e.=32%

 $[\alpha]_D^{25} -6.7$ (*c*=0.75, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (2*R*,3*S*)

(+)-(R)-4-Hydroxy-[2,2]-paracyclophane

E.e.=98%

 $[\alpha]_D^{20} = +8.1$ (*c* 1.0, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: *R*

(+)-(S)-4-Acetoxy-[2,2]-paracyclophane

E.e.=96%

 $[\alpha]_D^{20} = +40.3$ (*c* 1.0, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: *S*


(R)-4-Hydroxytetralone

E.e.=95% (by NMR)

 $[\alpha]_D^{27} = -35.5$ (*c* 1.0, CHCl₃)


Source of chirality: enzymatic hydrolysis

Absolute configuration: *R*




$C_{12}H_{12}O_3$
(*S*)-4-Acetoxytetralone

E.e. >96% (by NMR)
 $[\alpha]_D^{27} = -80.4$ (*c* 1.0, $CHCl_3$)
 Source of chirality: enzymatic hydrolysis
 Absolute configuration: *S*




$C_9H_8O_2$
(*S*)-3-Hydroxyindanone

E.e. >96% (by NMR)
 $[\alpha]_D^{27} = +99.5$ (*c* 0.9, $CHCl_3$)
 Source of chirality: enzymatic transesterification
 Absolute configuration: *S*




$C_{11}H_{10}O_3$
(*R*)-3-Acetoxyindanone

E.e. = 85% (by NMR)
 $[\alpha]_D^{27} = -8.9$ (*c* 1.2, $CHCl_3$)
 Source of chirality: enzymatic transesterification
 Absolute configuration: *R*



E.e. = 100%
 $[\alpha]_D^{20} = +148.8$ (*c* 0.5, $EtOH$)
 Source of chirality: (*S*)-2,2'-dimethylbiphenyl-6,6'-dicarboxylic acid
 Absolute configuration: (*S*)




C₂₂H₁₈O₄
(S)-2,2'-Bis(methoxycarbonylethynyl)-6,6'-dimethyl-1,1'-biphenyl

E.e. = 100%

[α]_D²⁰ = +185.4 (c 0.5, MeOH)

Source of chirality: (S)-2,2'-dimethylbiphenyl-6,6'-dicarboxylic acid

Absolute configuration: (S)




C₁₈H₁₄Br₄
(S)-2,2'-Bis(2,2-dibromoethenyl)-6,6'-dimethyl-1,1'-biphenyl

E.e. = 100%

[α]_D²⁰ = +65.1 (c 1.1, EtOH)

Source of chirality: (S)-2,2'-dimethylbiphenyl-6,6'-dicarboxylic acid

Absolute configuration: (S)



C₂₀H₁₆N₂O₂
(S)-2,2'-Bis(carbamoylethynyl)-6,6'-dimethyl-1,1'-biphenyl

E.e. = 100%

[α]_D²⁰ = +153.5 (c 0.5, MeOH)

Source of chirality: (S)-2,2'-dimethylbiphenyl-6,6'-dicarboxylic acid

Absolute configuration: (S)




C₈H₁₀O
(1R,4S)-2-Hydroxymethylbicyclo[2.2.1]hepta-2,5-diene


[α]_D²⁰ = -1.5 (c = 0.83, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1R,4S

 $C_8Cl_6H_4O$ (1*S*,4*R*)-2-Hydroxymethyl-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hepta-2,5-diene $[\alpha]_D^{20} = -7.3$ ($c = 1.66$, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,4*R* $C_{10}H_{12}O_2$ (1*S*,4*R*)-2-Acetoxyethylbicyclo[2.2.1]hepta-2,5-diene $[\alpha]_D^{20} = -2.4$ ($c = 0.66$, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,4*R* $C_{10}Cl_6H_6O_2$ (1*R*,4*S*)-2-Acetoxyethyl-1,4,5,6,7,7-hexachlorobicyclo[2.2.1]hepta-2,5-diene $[\alpha]_D^{20} = +4.1$ ($c = 1.33$, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,4*S* $C_6H_6F_3NO \cdot HCl$


(S)-2,2,2-Trifluoro-1-furan-2-yl-ethylamine hydrochloride

E.e. = 88%

 $[\alpha]_D^{25} 5.5$ (c 2, MeOH)

Source of chirality: enantioselective reduction

Absolute configuration: (S)




$C_6H_6F_3NO \cdot HCl$
(*R*)-2,2,2-Trifluoro-1-furan-2-yl-ethylamine hydrochloride

E.e.=86%

 $[\alpha]_D^{25} -5.35 (c\ 2, MeOH)$

Source of chirality: enantioselective reduction


Absolute configuration: (*R*)

$C_3H_4F_3NO_2$
(*S*)-3,3,3-Trifluoroalanine

E.e.=88%

 $[\alpha]_D^{25} -13.65 (c\ 1, MeOH)$

Source of chirality: enantioselective reduction


Absolute configuration: (*S*)

$C_3H_4F_3NO_2$
(*R*)-3,3,3-Trifluoroalanine

E.e.=86%

 $[\alpha]_D^{25} 13.3 (c\ 1, MeOH)$

Source of chirality: enantioselective reduction


Absolute configuration: (*R*)

$C_{19}H_{24}O_6$
Ethyl 5,6-dideoxy-1,2-O-isopropylidene-3-O-benzyl- α -D-xylo-hept-5-enofuranuronate

 $[\alpha]_D = -27.2 (c=1, CHCl_3)$


Source of chirality: D-glucose

Absolute configuration: (2*R*,3*S*,4*R*)

5,6-Dideoxy-3-O-benzyl-1,2-O-isopropylidene- α -D-xylo-heptofuranose $[\alpha]_D = -15.2$ ($c = 1$, CHCl₃)


Source of chirality: D-glucose

Absolute configuration: (2R,3S,4R)

7-Azido-3-O-benzyl-1,2-O-isopropylidene-5,6,7-trideoxy- α -D-xylo-heptofuranose $[\alpha]_D = -49.1$ ($c = 1$, CHCl₃)


Source of chirality: D-glucose

Absolute configuration: (2R,3S,4R)

3-O-Benzyl-7-tert-butoxycarbonylamino-1,2-O-isopropylidene-5,6,7-trideoxy- α -D-xylo-heptofuranose $[\alpha]_D = -32.2$ ($c = 1.25$, CHCl₃)


Source of chirality: D-glucose

Absolute configuration: (2R,3S,4R)


7-tert-Butoxycarbonylamino-1,2-O-isopropylidene-5,6,7-trideoxy- α -D-xylo-heptofuranose $[\alpha]_D = -9.29$ ($c = 1$, CHCl₃)

Source of chirality: D-glucose


Absolute configuration: (2R,3S,4R)

 $C_{15}H_{27}NO_6$ 7-*tert*-Butoxycarbonylamino-1,2-*O*-isopropylidene-5,6,7-trideoxy- α -D-*ribo*-heptofuranose $[\alpha]_D = +10.0$ ($c = 1.1$, CHCl₃)


Source of chirality: D-glucose

Absolute configuration: (2*R*,3*R*,4*R*) $C_{29}H_{39}NO_6$ N-Benzyl-3-*O*-benzyl-7-*tert*-butoxycarbonylamino-1,2-*O*-isopropylidene-5,6,7-trideoxy- α -D-*ribo*-heptofuranose $[\alpha]_D = +48.5$ ($c = 1$, CHCl₃)

Source of chirality: D-glucose


Absolute configuration: (2*R*,3*R*,4*R*) $C_{27}H_{37}NO_6$ Methyl 7-*N*-benzylamino-3-*O*-benzyl-7-*tert*-butoxycarbonylamino-5,6,7-trideoxy- α /β-D-*ribo*-heptofuranoside $[\alpha]_D = -10.2$ ($c = 1$, CHCl₃)

Source of chirality: D-glucose


Absolute configuration: (2*R*,3*R*,4*R*) $C_{34}H_{43}NO_6$ Methyl 7-*N*-benzylamino-7-*tert*-butoxycarbonylamino-2,3-di-*O*-benzyl-5,6,7-trideoxy- α /β-D-*ribo*-heptofuranoside $[\alpha]_D = -12.3$ ($c = 1$, CHCl₃)

Source of chirality: D-glucose


Absolute configuration: (2*R*,3*R*,4*R*)




$C_{33}H_{41}NO_6$
7-N-Benzylamino-7-*tert*-butoxycarbonylamino-2,3-di-*O*-benzyl-5,6,7-trideoxy- α/β -D-ribo-heptofuranose







$C_{33}H_{43}NO_6$
1N-Benzyl-N-(*tert*-butoxycarbonyl)-5,6-di-benzyloxy-4,7-dihydroxy-(4R,5R,6S)-heptylamine




$C_{39}H_{57}NO_6Si$
1N-Benzyl-N-(*tert*-butoxycarbonyl)-5,6-di-benzyloxy-4-hydroxy-7-(*tert*-butyldimethylsilyloxy)-(4R,5R,6S)-heptylamine





$C_{39}H_{56}N_4O_5Si$
1N-Benzyl-N-(*tert*-butoxycarbonyl)-4-azido-5,6-di-benzyloxy-7-(*tert*-butyldimethylsilyloxy)-(4S,5R,6S)-heptylamine

1*N*-Benzyl-*N*-(*tert*-butoxycarbonyl)-5,6-di-benzyloxy-7-(*tert*-butyldimethylsilyloxy)-4-(*tert*-butoxycarbonylamino)-(4*S*,5*R*,6*S*)-heptylamine1*N*-Benzyl-*N*-(*tert*-butoxycarbonyl)-5,6-di-benzyloxy-7-hydroxy-4-(*tert*-butoxycarbonylamino)-(4*S*,5*R*,6*S*)-heptylamineMethyl 7-*N*-benzyl-*N*-(*tert*-butoxycarbonyl)-2,3-di(benzyloxy)-4-(*tert*-butoxycarbonylamino)-(2*R*,3*R*,4*S*)-heptanoate $C_{22}H_{32}N_2O_2$
(2*R*,3*S*,4*S*,5*R*)-*N,N,N',N'*-Tetramethyl-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane


$[\alpha]_D^{20} = -4.2 (c = 2.4, CHCl_3)$
Source of chirality: diastereomerically pure
starting material
Absolute configuration: (2*R*,3*S*,4*S*,5*R*)

(2R,3S,4S,5R)-*N,N'*-Di-*n*-butyl-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane $[\alpha]_D^{20} = -89.3$ ($c = 2.5$, CHCl₃)



Source of chirality: diastereomerically pure starting material

Absolute configuration: (2*R*,3*S*,4*S*,5*R*)(2R,3S,4S,5R)-*N,N*-Dibenzyl-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane $[\alpha]_D^{20} = -75.3$ ($c = 3.1$, CHCl₃)

Source of chirality: diastereomerically pure starting material


Absolute configuration: (2*R*,3*S*,4*S*,5*R*)(4*S*)-Phenyl-3-((*S*)-1'-(nitromethyl)propyl-3'-phenyl)oxazolidin-2-one $[\alpha]_D = +62.8$ ($c = 0.70$, CHCl₃)

Source of chirality: electrochemically induced conjugate addition

Absolute configuration: (4*S*,1'*S*)(4*S*)-Benzyl-3-((*S*)-1'-(nitromethyl)propyl-3'-phenyl)oxazolidin-2-one $[\alpha]_D = +29.7$ ($c = 0.875$, CHCl₃)

Source of chirality: electrochemically induced conjugate addition


Absolute configuration: (4*S*,1'*S*)



$C_{15}H_{26}N_2O_4$
(4*S*)-*tert*-Butyl-3-((*S*)-1'-cyclohexyl-2'-nitroethyl)oxazolidin-2-one

$[\alpha]_D = +52.6$ ($c = 0.57$, $CHCl_3$)


Source of chirality: electrochemically induced conjugate addition
Absolute configuration: (4*S*,1'*S*)



$C_{16}H_{22}N_2O_4$
(4*S*)-*iso*-Propyl-3-((*S*)-1'-(nitromethyl)propyl-3'-phenyl)oxazolidin-2-one

$[\alpha]_D = +45.7$ ($c = 0.70$, $CHCl_3$)

Source of chirality: electrochemically induced conjugate addition
Absolute configuration: (4*S*,1'*S*)




$C_{44}H_{40}O_2P_2$
(*S*)-2,2'-Bis(diphenylphosphino)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl

E.e. >99% (from *S*-BINOL)

$[\alpha]_D = -82.0$ (c 1.0, THF)

Source of chirality: direct synthesis from (*S*)-BINOL
Absolute configuration: *S*




$C_{44}H_{42}N_2P_2$
(*R*)-2,2'-Bis(diphenylphosphinoamino)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl

E.e. >99% (from *R*-BINAM)

$[\alpha]_D = -47.0$ (c 1.0, CH_2Cl_2)

Source of chirality: direct synthesis from (*R*)-BINAM
Absolute configuration: *R*




C₁₅H₂₂O₄

Ethyl (2R,3R,4R,5S)-3,5-dihydroxy-2,4-dimethyl-5-phenylpentanoate

[α]_D²² -5.5 (*c* 1.83, CHCl₃)

Source of chirality: enantioselective aldol reaction

Absolute configuration: (2*R*,3*R*,4*R*,5*S*)




C₁₅H₂₂O₄

Ethyl (2*S*,3*R*,4*R*,5*S*)-3,5-dihydroxy-2,4-dimethyl-5-phenylpentanoate

[α]_D²² -8.3 (*c* 1.08, CHCl₃)

Source of chirality: enantioselective aldol reaction

Absolute configuration: (2*S*,3*R*,4*R*,5*S*)




C₁₅H₂₂O₄

Ethyl (2*S*,3*S*,4*S*,5*S*)-3,5-dihydroxy-2,4-dimethyl-5-phenylpentanoate

[α]_D²² -24.0 (*c* 0.25, CHCl₃)

Source of chirality: enantioselective aldol reaction

Absolute configuration: (2*S*,3*S*,4*S*,5*S*)




C₁₅H₂₂O₄

Ethyl (2*R*,3*S*,4*S*,5*S*)-3,5-dihydroxy-2,4-dimethyl-5-phenylpentanoate

[α]_D²² -50.0 (*c* 0.50, CHCl₃)


Source of chirality: enantioselective aldol reaction

Absolute configuration: (2*R*,3*S*,4*S*,5*S*)




$C_{10}H_{11}NO$
(*S*)-4-(*p*-Tolyl)-2-azetidinone)

E.e.=99% by GC on CP-Chirasil-Dex CB column

 $[\alpha]_D^{25}=-125.5$ ($c=0.5$, EtOH)Source of chirality: lipase PS-catalyzed butyrylation followed by $NH_4OH/MeOH$ treatmentAbsolute configuration: *S*

$C_{12}H_{18}ClNO_2$
Ethyl (*S*)-3-amino-3-(*p*-tolyl)-propionate hydrochloride

E.e.=97% by GC on Chirasil-L-Val column after derivatization with hexanoic anhydride


 $[\alpha]_D^{25}=+12.9$ ($c=1.9$, EtOH)Source of chirality: synthesis from its chiral β -lactam precursorAbsolute configuration: *S*

$C_{11}H_{13}NO_2$
(*S*)-1-Hydroxymethyl-4-(*p*-tolyl)-2-azetidinone

E.e.=95% by GC on CP-Chirasil-Dex CB column

 $[\alpha]_D^{25}=-168.0$ ($c=0.5$, EtOH)

Source of chirality: lipase PS-catalyzed butyrylation

Absolute configuration: *S*


$C_{15}H_{19}NO_3$
(*S*)-1-Butyryloxymethyl-4-(*p*-tolyl)-2-azetidinone

E.e.=97% by GC on CP-Chirasil-Dex CB column

 $[\alpha]_D^{25}=-62$ ($c=1$, EtOH)


Source of chirality: lipase PS-catalyzed butyrylation

Absolute configuration: *S*




C₉H₉NO
(*R*)-4-Phenyl-2-azetidinone

E.e.=97% by GC on CP-Chirasil-Dex CB column
 $[\alpha]_D^{25}=+132.4$ (*c*=0.5, EtOH)
 Source of chirality: lipase PS-catalyzed butyrylation followed by NH₄OH/MeOH treatment
 Absolute configuration: *R*




C₁₁H₁₆ClNO₂
Ethyl (*R*)-3-amino-3-phenylpropionate hydrochloride

E.e.=95% by GC on Chirasil-L-Val column after derivatization with hexanoic anhydride
 $[\alpha]_D^{25}=-11.4$ (*c*=0.35, EtOH)
 Source of chirality: synthesis from its chiral β -lactam precursor
 Absolute configuration: *R*



C₁₀H₁₁NO₂
(*S*)-1-Hydroxymethyl-4-phenyl-2-azetidinone

E.e.=98% by GC on CP-Chirasil-Dex CB column
 $[\alpha]_D^{25}=-166.7$ (*c*=1, EtOH)
 Source of chirality: lipase PS-catalyzed butyrylation
 Absolute configuration: *S*



C₁₄H₁₇NO₃
(*R*)-1-Butyryloxymethyl-4-phenyl-2-azetidinone

E.e.=97% by GC on CP-Chirasil-Dex CB column
 $[\alpha]_D^{25}=+61.4$ (*c*=1, EtOH)
 Source of chirality: lipase PS-catalyzed butyrylation
 Absolute configuration: *R*